- Home
- EOSE vs WGS Comparison
EOSE vs WGS Comparison
Compare EOSE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EOSE | WGS |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Miscellaneous | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EOSE | WGS |
|---|---|---|
| Price | $11.60 | $91.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $12.79 | ★ $138.13 |
| AVG Volume (30 Days) | ★ 23.4M | 813.7K |
| Earning Date | 03-03-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $63,458,000.00 | ★ $402,190,000.00 |
| Revenue This Year | $881.55 | $41.21 |
| Revenue Next Year | $219.15 | $24.88 |
| P/E Ratio | ★ N/A | $1,288.84 |
| Revenue Growth | ★ 324.10 | 50.50 |
| 52 Week Low | $3.07 | $55.17 |
| 52 Week High | $19.86 | $170.87 |
Technical Indicators
Market Signals| Indicator | EOSE | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.14 | 36.55 |
| Support Level | $10.88 | $81.55 |
| Resistance Level | $13.36 | $101.94 |
| Average True Range (ATR) | 1.51 | 6.53 |
| MACD | -0.49 | 0.84 |
| Stochastic Oscillator | 9.27 | 36.85 |
Price Performance
Historical ComparisonAbout EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.